The NAD+ nasal spray offers a delivery route that addresses the central challenge of NAD+ supplementation — bioavailability — by bypassing the gastrointestinal tract entirely and delivering nicotinamide adenine dinucleotide directly to the nasal mucosa for absorption into both systemic circulation and, potentially, the central nervous system via nose-to-brain transport pathways.

The NAD+ nasal spray offers a delivery route that addresses the central challenge of NAD+ supplementation — bioavailability — by bypassing the gastrointestinal tract entirely and delivering nicotinamide adenine dinucleotide directly to the nasal mucosa for absorption into both systemic circulation and, potentially, the central nervous system via nose-to-brain transport pathways. NAD+ is the essential coenzyme for cellular energy production, DNA repair, and sirtuin activation, and its levels decline by approximately 50% between young adulthood and age 60 — but delivering intact NAD+ to cells has historically been limited by the molecule’s poor oral bioavailability and its large molecular weight relative to traditional nasal spray peptides.

The PSPeptides NAD+ Spray provides an alternative to both oral NAD+ precursors (NMN, NR) and intravenous NAD+ infusions, occupying a practical middle ground: more direct than precursors that require enzymatic conversion, more accessible than IV infusions that require clinical administration. For a comprehensive overview of NAD+ biology and its role in aging, see our complete NAD+ research guide. PSPeptides also carries NAD+ as an injectable vial and as oral tablets, providing all three delivery formats for researchers studying NAD+ biology.

Why Deliver NAD+ as a Nasal Spray?

Understanding why the nasal spray format matters for NAD+ requires understanding the bioavailability challenges that limit other delivery routes.

The oral problem: NAD+ is a dinucleotide with a molecular weight of 663.4 Da — substantially larger than most orally bioavailable compounds. When taken orally, NAD+ faces enzymatic degradation in the GI tract, first-pass hepatic metabolism in the liver, and cellular uptake barriers in the intestinal lining. This is precisely why most NAD+ supplementation research has focused on smaller precursors like NMN (334 Da) and NR (255 Da) — they are small enough for reasonable oral absorption and then undergo enzymatic conversion to NAD+ inside cells. However, this conversion depends on the activity of specific enzymes (NMNAT for NMN, NRK then NMNAT for NR), and the efficiency of these conversion steps varies between tissues, between individuals, and with age.

The IV solution and its limitations: Intravenous NAD+ infusion bypasses all absorption barriers, delivering the complete molecule directly into the bloodstream at known concentrations. This is why IV NAD+ has become popular in clinical settings. However, IV infusions require clinical supervision, IV access, and 2-4 hours of infusion time — making them impractical for daily research protocols and inaccessible for most researchers outside of clinical environments.

The nasal spray advantage: The nasal mucosa provides a highly vascularized absorption surface that delivers substances directly into systemic circulation while partially bypassing first-pass hepatic metabolism. For NAD+, this means the intact dinucleotide molecule contacts the thin nasal epithelium and can be absorbed into the rich capillary network underlying the nasal tissue without first passing through the digestive tract or liver. The nasal spray format combines meaningful bioavailability with practical convenience — no IV access, no clinic visits, no multi-hour infusions. Just spray, absorb, done.

NAD+ Nasal Spray and Brain Health: The Nose-to-Brain Pathway

Beyond systemic absorption, the nasal spray format offers a particularly intriguing possibility for NAD+ research: nose-to-brain transport. The same olfactory and trigeminal nerve pathways that deliver peptides like Semax and Selank directly to brain tissue may also transport NAD+ — bypassing the blood-brain barrier that limits how much circulating NAD+ reaches CNS tissue when administered systemically.

This is significant because the brain is among the most metabolically demanding organs in the body, consuming approximately 20% of total body energy despite comprising only 2% of body weight. Neuronal mitochondria rely on NAD+ for ATP production, and NAD+-dependent enzymes — including PARPs for DNA repair and sirtuins (particularly SIRT1 and SIRT3) for metabolic regulation — are essential for neuronal health and survival. Age-related NAD+ decline in brain tissue has been associated with mitochondrial dysfunction, impaired DNA repair, and neuroinflammation — all processes implicated in neurodegenerative disease and age-related cognitive decline.

Published research on NAD+ and neurodegeneration has demonstrated that NAD+ augmentation in brain tissue can reduce amyloid pathology, improve mitochondrial function, and support neuronal survival in preclinical neurodegeneration models. The potential for the NAD+ nasal spray to deliver the coenzyme directly to brain tissue via nose-to-brain pathways — rather than relying on systemic administration and BBB penetration — makes it particularly relevant for neurological aging research. Additionally, NAD+ is required for the activity of PARP enzymes that repair DNA damage in neurons — damage that accumulates with age and contributes to neurodegenerative pathology. By providing NAD+ directly to brain tissue, the nasal spray may support the DNA repair capacity that protects neurons from the genomic instability associated with aging. For researchers studying other compounds that address brain aging through mitochondrial mechanisms, our MOTS-C guide covers AMPK-mediated mitochondrial signaling, and our SS-31 guide covers cardiolipin stabilization in mitochondrial membranes.

NAD+ Nasal Spray and Sirtuin-Dependent Aging Biology

The relationship between NAD+ and sirtuins — the enzyme family most closely associated with longevity — is central to understanding why the NAD+ nasal spray matters for aging research. Sirtuins (SIRT1-7) are NAD+-dependent deacetylases and ADP-ribosyltransferases that regulate gene expression, mitochondrial function, inflammation, and cellular stress responses. Without adequate NAD+, sirtuins cannot function — making NAD+ availability the rate-limiting factor for sirtuin activity across all seven family members.

SIRT1 (nuclear) regulates inflammatory pathways through NF-κB suppression, glucose metabolism, and fat mobilization. SIRT3 (mitochondrial) controls mitochondrial protein acetylation, antioxidant defenses, and fatty acid oxidation. SIRT6 (nuclear) is essential for DNA damage repair and telomere maintenance. All require NAD+ as their consumable substrate — and when NAD+ levels decline with age, all three are impaired simultaneously, creating a cascade of dysfunction across genomic stability, mitochondrial function, and metabolic regulation.

The NAD+ nasal spray is relevant to sirtuin research because it delivers the coenzyme that sirtuins directly consume. Precursor-based approaches (NMN, NR) provide indirect support by increasing the raw material for NAD+ biosynthesis, but the conversion efficiency varies between tissues and individuals. Direct NAD+ delivery through the nasal spray eliminates conversion variability and provides the active substrate immediately. For brain-specific sirtuin research — where SIRT1 and SIRT6 play critical roles in neuronal gene regulation and DNA repair — the potential nose-to-brain delivery of the NAD+ nasal spray offers a targeted approach to supporting CNS sirtuin function that systemic administration may not match.

How NAD+ Works: The Biology Behind the Spray

NAD+ functions through two fundamentally different biochemical roles that together explain why its decline with age is so consequential.

Redox coenzyme: NAD+ acts as an electron carrier in hundreds of metabolic reactions, shuttling electrons between metabolic intermediates in glycolysis, the TCA cycle, and oxidative phosphorylation. This redox cycling (NAD+ ↔ NADH) drives ATP production in every cell. The cycling is reversible — NAD+ and NADH interconvert continuously without net consumption.

Consumable substrate: This is the role that causes NAD+ to decline with age. PARP enzymes (for DNA repair), sirtuins (for gene regulation), and CD38 (an ectoenzyme that increases with aging-related inflammation) all consume NAD+ as a substrate, breaking it apart permanently. When DNA damage accumulates, PARP activation increases, consuming more NAD+. When CD38 expression rises with inflammaging, more NAD+ is degraded. The result is a progressive decline in the total NAD+ pool — approximately 50% reduction by age 60 in human tissue.

The NAD+ nasal spray delivers the complete, active coenzyme — not a precursor that requires enzymatic conversion. This bypasses the rate-limiting conversion steps (NRK, NMNAT) that precursors depend on, potentially providing more direct NAD+ restoration to tissues reached by nasal absorption. For researchers studying how NAD+ biology connects to the broader longevity peptide landscape, NAD+ addresses aging through metabolic and DNA repair mechanisms that complement peptide approaches like epitalon (telomere maintenance) and GHK-Cu (gene expression modulation for tissue regeneration).

Why Do NAD+ Levels Decline with Age — and How the Spray Helps

The age-related NAD+ decline that the nasal spray aims to address is driven by three converging mechanisms that accelerate with aging. CD38 upregulation — CD38 is an ectoenzyme that degrades NAD+ and its precursors, and its expression increases with the chronic low-grade inflammation (inflammaging) that characterizes biological aging. Published research has demonstrated that CD38 is the primary driver of age-related NAD+ decline in multiple tissues, and genetic deletion of CD38 in animal models prevents the decline entirely. CD38 expression is stimulated by inflammatory cytokines including TNF-α and IL-6, creating a direct mechanistic link between the chronic low-grade inflammation of aging (inflammaging) and NAD+ depletion — each condition worsening the other in a self-reinforcing cycle that the NAD+ spray can help address by providing exogenous NAD+ to supplement the depleted endogenous pool. Increased PARP activity — as DNA damage accumulates with age from oxidative stress and environmental exposures, PARP enzymes are activated more frequently, consuming NAD+ for repair. Reduced NAMPT expression — the salvage pathway enzyme that recycles nicotinamide back into NAD+ becomes less efficient with age, reducing regeneration capacity. The net result is a progressive and accelerating NAD+ deficit that characterizes biological aging across virtually every tissue and organ system studied.

The convergence of increased consumption (CD38 + PARP) and decreased regeneration (reduced NAMPT) produces the progressive NAD+ deficit. The nasal spray addresses this deficit by providing exogenous NAD+ that supplements the depleted endogenous pool — and the intranasal route may provide more efficient delivery to brain tissue (where NAD+ decline has the most consequential effects on cognitive function and neuronal survival) than oral supplementation that must survive GI degradation, hepatic first-pass metabolism, and BBB transit.

For researchers studying how NAD+ depletion connects to the broader aging process, our longevity peptide guide covers how different compounds address different hallmarks of aging. NAD+ intersects with at least five hallmarks simultaneously — genomic instability, epigenetic alterations, mitochondrial dysfunction, deregulated nutrient sensing, and cellular senescence — making it one of the most mechanistically broad anti-aging interventions available.

NAD+ Spray vs Vial vs Tablets: Choosing the Right Format

PSPeptides offers all three formats — spray, vial, and tablets — enabling researchers to select the delivery route that best matches their specific research design. The spray is particularly suited for protocols investigating brain NAD+ biology, where nose-to-brain delivery may provide a CNS advantage over systemic administration.

NAD+ Nasal Spray Dosing and Research Protocols

The PSPeptides NAD+ Nasal Spray is supplied pre-formulated and ready to use — no reconstitution required. Each actuation delivers a calibrated dose of NAD+ to the nasal mucosa. For optimal absorption, administer with head tilted slightly back, directing the spray toward the upper nasal cavity. Alternate nostrils to distribute absorption across the full mucosal surface area.

Timing of administration may be relevant depending on the research question. NAD+ is essential for energy metabolism, so morning administration aligns with the natural circadian peak in metabolic demand. For researchers studying NAD+’s role in DNA repair (via PARP enzymes), consistent daily dosing maintains the NAD+ pool at levels sufficient to support PARP activation when DNA damage occurs. For sleep-related research — given that NAD+ influences circadian clock gene expression through sirtuin-mediated deacetylation — the timing relationship between NAD+ administration and the circadian cycle may be an experimental variable worth controlling.

Storage at 2-8°C per standard peptide protocols. For comprehensive storage guidance, see our peptide storage guide. For researchers who prefer the injectable format, our reconstitution guide and dosage calculator cover preparation procedures.

Combining NAD+ Spray with Other Longevity Compounds

NAD+’s mechanism connects to several other compounds in the PSPeptides catalog through shared metabolic pathways. The most mechanistically direct connection is with 5-Amino-1MQ, which inhibits NNMT — the enzyme that depletes NAD+ precursors by methylating nicotinamide. NAD+ spray increases the supply of the active coenzyme, while 5-Amino-1MQ prevents the enzymatic waste that depletes the precursor pool. These complementary approaches — increasing supply and reducing waste — represent a theoretically synergistic combination for NAD+ restoration research.

For mitochondrial-focused protocols, combining NAD+ spray with the MOTS-C Spray addresses two different aspects of mitochondrial function: NAD+ provides the substrate for electron transport chain activity and sirtuin-mediated mitochondrial regulation, while MOTS-C activates AMPK metabolic signaling — a master regulator of cellular energy balance. The Epitalon Spray adds a third longevity dimension — telomerase activation and melatonin restoration — for comprehensive anti-aging research protocols that address mitochondrial energy (NAD+), metabolic signaling (MOTS-C), and telomere maintenance (Epitalon) simultaneously through non-overlapping mechanisms.

The spray format makes these multi-compound longevity protocols practical for daily research use. Rather than preparing multiple injectable vials with reconstitution, syringe loading, and injection site rotation, researchers can administer sequential nasal sprays in under a minute total. This convenience translates directly to better protocol compliance — particularly important for longevity research where extended treatment durations are necessary to observe meaningful biological outcomes. For researchers interested in how these compounds fit into the broader peptide landscape, our complete guide to peptides provides foundational context, and our peptide half-life chart helps researchers understand the pharmacokinetic considerations for timing multi-spray protocols.

Further Reading

For additional peer-reviewed research, see: PubMed research on NAD+ and brain aging.

Understanding nad+ nasal spray is essential for researchers navigating this rapidly evolving field in 2026.

Frequently Asked Questions

Why use a NAD+ nasal spray instead of NMN or NR supplements?

NMN and NR are NAD+ precursors that require enzymatic conversion to become active NAD+. The nasal spray delivers the complete, active coenzyme directly — bypassing the rate-limiting conversion steps. Additionally, nasal delivery partially bypasses first-pass hepatic metabolism and may provide nose-to-brain transport for CNS NAD+ delivery that oral precursors cannot achieve.

Can the NAD+ nasal spray reach the brain?

The nasal cavity contains olfactory and trigeminal nerve pathways that can transport substances directly to the brain, bypassing the blood-brain barrier. While specific nose-to-brain pharmacokinetic data for NAD+ is limited, this transport mechanism is well-established for other molecules delivered intranasally, and the theoretical basis for NAD+ nose-to-brain delivery is scientifically plausible.

How does the NAD+ spray compare to IV NAD+ infusions?

IV infusions provide the highest systemic bioavailability but require clinical supervision, IV access, and 2-4 hours of infusion time. The nasal spray provides a practical daily alternative with meaningful absorption through the nasal mucosa — no clinic visits, no IV lines, no multi-hour sessions. Both deliver the complete NAD+ molecule rather than precursors.

Can the NAD+ spray be combined with other PSPeptides sprays?

Yes. The NAD+ spray combines mechanistically with MOTS-C spray (AMPK mitochondrial signaling), Epitalon spray (telomerase activation), and 5-Amino-1MQ (NNMT inhibition to preserve NAD+ precursors). Each addresses different aspects of cellular aging through non-overlapping pathways.

All PSPeptides products are sold exclusively for research and laboratory use.